HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SPRY
ARS Pharmaceuticals, Inc.
There isn't enough reported data to score SPRY yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SPRY Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
SPRY's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SPRY PE Valuation
SPRY has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SPRY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect SPRY's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over SPRY on earnings, with more consistent year-over-year improvement.
SPRY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.01 | -$1.20 |
| Q2 2026 | -$2.17 | -$1.68 |
| Q1 2026 | -$2.00 | -$1.84 |
| Q4 2025 | -$1.74 | -2275% |
| Q3 2025 | -$0.81 | -$0.30 |
| Q2 2025 | -$0.49 | -$0.02 |
| Q1 2025 | -$0.16 | +$0.36 |
| Q4 2024 | $0.08 | +$0.65 |
SPRY is still losing money, but less than at its worst: $2.01 per share over the past year, against $2.72 at its worst in early 2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SPRY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SPRY on profitability, with a higher operating margin.
SPRY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.7M | +16% |
| Q2 2026 | $33.7M | +114% |
| Q1 2026 | $22.7M | +184% |
| Q4 2025 | $28.1M | -68% |
| Q3 2025 | $32.5M | +1472% |
| Q2 2025 | $15.7M | +3043% |
| Q2 2024 | $500K | +4900% |
SPRY's revenue is recovering but still below its 2024 peak: $38M last quarter, up 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -91% | +73 points |
| Q2 2026 | -183% | +120 points |
| Q1 2026 | -265% | +201 points |
| Q4 2025 | -148% | -202 points |
| Q3 2025 | -164% | +888 points |
| Q2 2025 | -303% | +2765 points |
| Q1 2025 | -466% | N/A |
| Q4 2024 | 55% | N/A |
SPRY's operating margin was −91% last quarter, up 73 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SPRY on cash generation, producing positive trailing cash flow while its opponent burns cash.
SPRY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$33.7M | +$13.5M |
| Q2 2026 | -$60.9M | -$21.3M |
| Q1 2026 | -$44.9M | -$4.1M |
| Q4 2025 | -$43.5M | -204% |
| Q3 2025 | -$47.2M | -$32.6M |
| Q2 2025 | -$39.6M | -$32.3M |
| Q1 2025 | -$40.8M | -$34M |
| Q4 2024 | $41.7M | +$59M |
SPRY has burned cash in almost every quarter: −$183M over the past year, against −$86M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SPRY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SPRY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +373K shares |
| 1 year | +0.9% | +878K shares |
| 3 years | +4.3% | +4.1M shares |
| 5 years | +186% | +64.8M shares |
| Available history | +201% | +66.6M shares |
SPRY has 100M diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SPRY Net Leverage
SPRY's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SPRY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 14.3 | Oversold |
SPRY's weekly RSI is 36 (neutral) and its Stochastic is 14 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SPRY PE vs Healthcare Sector
| Metric | SPRY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SPRY has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SPRY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.80 | 0.3% above |
| 20 week MA | $5.13 | 26% below |
| 50 week MA | $7.64 | 50% below |
| 100 week MA | $10.2 | 63% below |
| 200 week MA | $9.31 | 59% below |
SPRY has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SPRY on returns for 2026, with the stronger performance.
SPRY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.0 | $35.8 | +43% |
| 2021 | $35.8 | $6.65 | -81% |
| 2022 | $6.65 | $8.08 | +22% |
| 2023 | $8.08 | $5.48 | -32% |
| 2024 | $5.48 | $10.8 | +97% |
| 2025 | $10.8 | $11.4 | +5.5% |
| 2026 YTD | $11.4 | $3.81 | -67% |
SPRY is down 67% so far in 2026, after finishing higher in four of the previous six years.